References
  1. Susanibar-Adaniya S, Barta SK. 2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management. Am J Hematol. 2021;96(5):617-629. doi:10.1002/ajh.26151
  2. Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma.Pathology. 2018;50(1):74-87. doi:10.1016/j.pathol.2017.09.006
  3. Friedberg JW, Fisher RI. Diffuse large B-cell lymphoma. Hematol Oncol Clin North Am. 2008;22(5):941-ix. doi:10.1016/j.hoc.2008.07.002
  4. Nedomova R, Papajik T, Prochazka V, Indrak K, Jarosova M. Cytogenetics and molecular cytogenetics in diffuse large B-cell lymphoma (DLBCL). Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013;157(3):239-247. doi:10.5507/bp.2012.085
  5. Solimando AG, Annese T, Tamma R, et al. New Insights into Diffuse Large B-Cell Lymphoma Pathobiology. Cancers (Basel). 2020;12(7):1869. Published 2020 Jul 11. doi:10.3390/cancers12071869
  6. Padala SA, Kallam A. Diffuse Large B Cell Lymphoma. In:StatPearls. Treasure Island (FL): StatPearls Publishing; August 2, 2021.
  7. Howell JM, Auer-Grzesiak I, Zhang J, Andrews CN, Stewart D, Urbanski SJ. Increasing incidence rates, distribution and histological characteristics of primary gastrointestinal non-Hodgkin lymphoma in a North American population. Can J Gastroenterol. 2012;26(7):452-456. doi:10.1155/2012/480160
  8. Lo Re G, Federica V, Midiri F, et al. Radiological Features of Gastrointestinal Lymphoma [published correction appears in Gastroenterol Res Pract. 2016;2016:9742102]. Gastroenterol Res Pract. 2016;2016:2498143. doi:10.1155/2016/2498143
  9. Shirwaikar Thomas A, Schwartz M, Quigley E. Gastrointestinal lymphoma: the new mimic. BMJ Open Gastroenterol. 2019;6(1):e000320. Published 2019 Sep 13. doi:10.1136/bmjgast-2019-000320
  10. Lodhi HT, Hussain Q, Munir A, Zafar F, Khan ZH. Primary Gastrointestinal Diffuse Large B-cell Lymphoma. Cureus. 2018;10(9):e3258. Published 2018 Sep 5. doi:10.7759/cureus.3258
  11. Ghai S, Pattison J, Ghai S, O’Malley ME, Khalili K, Stephens M. Primary gastrointestinal lymphoma: spectrum of imaging findings with pathologic correlation. Radiographics. 2007;27(5):1371-1388. doi:10.1148/rg.275065151
  12. Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood. 2010;116(24):5103-5110. doi:10.1182/blood-2010-07-259333
  13. Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(5):604-616. doi:10.1002/ajh.25460
  14. Zaarour M, Busack C, Munker R. Obstructing Duodenal Diffuse Large B-cell Lymphoma with Peritoneal Lymphomatosis with Exceptional Response to R-CHOP. Cureus. 2019;11(5):e4621. Published 2019 May 8. doi:10.7759/cureus.4621
  15. Pejša V, Prka Ž, Lucijanić M, et al. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients. Croat Med J. 2017;58(1):40-48. doi:10.3325/cmj.2017.58.40
  16. Sussman J, Varela NP, Cheung M, et al. Follow-up care for survivors of lymphoma who have received curative-intent treatment. Curr Oncol. 2016;23(5):e499-e513. doi:10.3747/co.23.3265